These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25394147)

  • 1. The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients.
    Gonzalez EO; Boix V; Deltoro MG; Aldeguer JL; Portilla J; Montero M; Belda EB; Abril V; Gutierrez F; Minguez C; Galindo J; Benirto C; Rodriguez MG; Giner L; Rubio P; Uso J; Llerena G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19643. PubMed ID: 25394147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of liver decompensation assessed in HIV/HCV co-infected individuals with advanced liver fibrosis: a faster countdown experience.
    Alves JP; Peres S; Borges F; Miranda AC; Baptista T; Ventura F; Antunes I; Nina J; Campos MJ; Aldir I; Mansinho K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19641. PubMed ID: 25394145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
    Tural C; Tor J; Sanvisens A; Pérez-Alvarez N; Martínez E; Ojanguren I; García-Samaniego J; Rockstroh J; Barluenga E; Muga R; Planas R; Sirera G; Rey-Joly C; Clotet B
    Clin Gastroenterol Hepatol; 2009 Mar; 7(3):339-45. PubMed ID: 19171202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?
    Saracino A; Bruno G; Scudeller L; Punzi G; Lagioia A; Ladisa N; Monno L; Angarano G
    J Clin Virol; 2014 Mar; 59(3):167-71. PubMed ID: 24461764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
    Gagliardini R; Rossetti B; Bianco C; Rusconi S; Colafigli M; Prinapori R; Francisci D; Fantauzzi A; Orofino G; Vignale F; Di Giambenedetto S; De Luca A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19818. PubMed ID: 25397562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count.
    Bonnard P; Lescure FX; Amiel C; Guiard-Schmid JB; Callard P; Gharakhanian S; Pialoux G
    J Viral Hepat; 2007 Nov; 14(11):806-11. PubMed ID: 17927617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.
    Kelleher TB; Mehta SH; Bhaskar R; Sulkowski M; Astemborski J; Thomas DL; Moore RE; Afdhal NH
    J Hepatol; 2005 Jul; 43(1):78-84. PubMed ID: 15894397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
    Macías J; Viloria MM; Rivero A; de los Santos I; Márquez M; Portilla J; Di Lello F; Camacho A; Sanz-Sanz J; Ojeda G; Mata R; Gómez-Mateos J; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):2083-8. PubMed ID: 22258426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
    HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
    Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Halfon P
    J Hepatol; 2008 May; 48(5):765-73. PubMed ID: 18314219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
    Maor Y; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P
    Haemophilia; 2006 Jul; 12(4):372-9. PubMed ID: 16834736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.
    Abad-Fernández M; Moreno A; Dronda F; del Campo S; Quereda C; Casado JL; Pérez-Elías MJ; Moreno S; Vallejo A
    AIDS; 2015 Feb; 29(4):401-9. PubMed ID: 25565497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
    Sanvisens A; Serra I; Tural C; Tor J; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Muga R
    J Viral Hepat; 2009 Jul; 16(7):513-8. PubMed ID: 19200132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
    Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
    J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring.
    Elesawy BH; Abd El Hafez A; Dorgham LS; El-Askary A
    Pathol Res Pract; 2014 Dec; 210(12):922-8. PubMed ID: 25123964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
    Calin R; Guiguet M; Desire N; Imbert-Bismut F; Munteanu M; Poynard T; Valantin MA; Stitou H; Katlama C; Thibault V
    J Clin Virol; 2013 Oct; 58(2):408-14. PubMed ID: 23958588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.